Eagle LogoPEPTIDE INITIATIVE

Peptide Database

Adipotide
Weight Management
AOD-9604
Weight Management
BPC-157
Healing & Recovery
Cagrilintide
Weight Management
CJC-1295
Growth Hormone
DSIP
Sleep & Recovery
Epithalon
Anti-Aging
GHK-Cu
Anti-Aging
GHRP-2
Growth Hormone
HCG
Hormone Support
Hexarelin
Growth Hormone
HGH
Growth Hormone
IGF-1 LR3
Growth Hormone
Kisspeptin
Hormone Support
Melanotan-2
Cosmetic
MOTS-C
Metabolic
NAD+
Anti-Aging
Oxytocin Acetate
Hormone Support
PEG-MGF
Recovery
PT-141
Sexual Health
Retatrutide
Weight Management
Selank
Cognitive
Semaglutide
Weight Management
Semax
Cognitive
Sermorelin
Growth Hormone
Snap-8
Cosmetic
SS-31
Mitochondrial
TB-500
Healing & Recovery
Tesamorelin
Growth Hormone
Thymosin Alpha-1
Immune
Tirzepatide
Weight Management
Total Peptides: 31
Back to Home
Kisspeptin
EfficacyHigh
Studies8
Participants187
StatusAvailable

Kisspeptin

Kisspeptin-54 / Kisspeptin-10

Kisspeptin is a neuropeptide encoded by the KISS1 gene that plays a critical role in regulating the hypothalamic-pituitary-gonadal (HPG) axis. It stimulates gonadotropin-releasing hormone (GnRH) secretion by binding to the GPR54/Kiss1R receptor, making it essential for reproductive function, puberty onset, and fertility. Originally discovered as a metastasis suppressor in certain cancers, kisspeptin has emerged as a promising therapeutic target for reproductive disorders including infertility, hypothalamic amenorrhea, and hypoactive sexual desire disorder.

Evidence-Based Combination Strategies

Kisspeptin + IVF Protocol

Evidence-Based
Evidence Base:
Phase II clinical trials (Dhillo et al., 2014)
N = 53 participants
Clinical Outcomes:
23% pregnancy rate with reduced OHSS risk compared to hCG triggering
Safety Profile:
Excellent safety profile with no ovarian hyperstimulation cases
Implementation Protocol:
Single kisspeptin-54 injection (6.4-12.8 nmol/kg) 36h post-gonadotropin

Kisspeptin + Hypothalamic Amenorrhea Treatment

Evidence-Based
Evidence Base:
Clinical case series (Jayasena et al., 2014)
N = 12 participants
Clinical Outcomes:
Restored LH/FSH pulsatility and menstrual function in 85% of patients
Safety Profile:
Well-tolerated with twice-weekly dosing protocol
Implementation Protocol:
Kisspeptin-54 6.4 nmol/kg subcutaneous twice weekly for 8 weeks

Kisspeptin + PCOS Management

Research-Based
Evidence Base:
Pilot study data (Jayasena et al., 2019)
N = 24 participants
Clinical Outcomes:
Induced ovulation in subset of anovulatory PCOS patients
Safety Profile:
No adverse effects with variable individual responses
Implementation Protocol:
Repeated kisspeptin-54 administration with cycle monitoring

Medical Disclaimer

Kisspeptin is in Phase 2 clinical trials for reproductive applications. This information is for educational purposes only and should not be construed as medical advice. Any clinical use should occur only under medical supervision in approved research or clinical settings.